Lecanemab in Early Alzheimers Disease
NEJM 388:9-21,80, van Dyck,A.H.,et al, 2023
Advances in Progressive Supranuclear Palsy: New Diagnostic Criteria, Biomarkers, and Therapeutic Approaches
Lancet Neurol 16:552-563, Boxer, A.L.,et al, 2017
Infarct Volume is a Pivotal Biomarker After Inter-Arterial Stroke Therapy
Stroke 43:1323-1330, Yoo,A.J.,et al, 2012
Paraneoplastic Calmodulin Kinase-Like Vesicle-Associated Protein (CAMKV) Autoimmune Encephalitis
Ann Neurol 96:21-33, Gilligan,M.,et al, 2024
Parkinsons Disease
NEJM 391:442-452, Tanner,C.M. & Ostrem,J.L., 2024
Clinical,Neuroimaging,and Genetic Markers in Cerebral Amyloid Angiopatny-Related Inflammation:A Systematic Review and Meta-Analusis
Stroke 54:178-188, Theodorou,A.,et al, 2023
Alzheimers Disease
Lancet 397:1577-1590, Scheltens, P.,et al, 2021
National Institute of Neurological Disorders and Stroke Consensus Diagnostic Criteria for Traumatic Encephalopathy Syndrome
Neurol 96:848-863, Katz, D.I.,et al, 2021
Mechanisms of Ischemic Stroke in Patients with Cancer
Ann Neurol 90:159-169, Navi, B.B.,et al, 2021
Controversy and Progress in Alzheimers Disease - FDA Approval of Aducanumab
NEJM 385:doi:10.1056/NEJMp2111320, Rabinovici, G.D., 2021
Circulating DNAs, a Marker of Neutrophil Extracellular Traposis and Cancer-Related Stroke
Stroke 50:2944-2947, Bang, O.Y.,et al, 2019
Practice Guide Update Summary: Mild Cognitive Impairment
Neurol 90:126-135, Petersen, R.C.,et al, 2018
Predicting Intracerebral Hemorrhage Expansion With Noncontrast Computed Tomography
Stroke 49:1163-1169, Morotti, A.,et al, 2018
Natalizumab-Associated PML
Neurol 88:1197-1205, Schwab, N.,et al, 2017
Noncontrast Computed Tomography Markers of Intracerebral Hemorrhage Expansion
Stroke 48:1120-1125, Boulouis, G.,et al, 2017
Diagnosis and Management of Dementia with Lewy Bodies
Neurol 89:88-100, McKeith, I.G.,et al, 2017
Conversion to Parkinson Disease in the PARS Hyposmic and Dopamine Transporter-Deficit Prodromal Court
JAMA Neurol 74:933-940,901, Jennings, D.,et al, 2017
Glial Fibrillary Acidic Protein Immunoglobulin G as Biomarker of Autoimmune Astrocytopathy: Analysis of 102 Patients
Ann Neurol 81:298-309, Flanagan, E.P.,et al, 2017
Statin-Associated Autoimmune Myopathy
NEJM 374:664-669, Mammen, A.L., 2016
A Clinical Approach to Diagnosis of Autoimmune Encephalitis
Lancet Neurol 15:391-404, Graus, F.,et al, 2016
A Clinical Approach to the Diagnosis of Traumatic Encephalopathy Syndrome
JAMA Neurol 73:743-749, Reams, N.,et al, 2016
Polymyalgia Rheumatica and Giant Cell Arteritis
JAMA 315:2442-2458, Buttgereit, F.,et al, 2016
Prevalence of Cerebral Amyloid Pathology in Persons without Dementia
JAMA 313-1924-1938,1913, Jansen, W.J.,et al, 2015
Antiamyloid Therapy for Alzheimers Disease - Are We on the Right Road?
NEJM 370:377-378, Karran, E. & Hardy, J., 2014
Parkinson Disease Subtypes
JAMA 71:499-504, Thenganatt, M. & Jankovic, J., 2014
Anti-HMGCR Autoantibodies in European Patients with Autoimmune Necrotizing Myopathies
Medicine 93:150-157, Allenbach, Y.,et al, 2014
The Autosomal Recessive Cerebellar Ataxias
NEJM 366:636-646, Anheim,M.,et al, 2012
CSF biomarkers in posterior cortical atrophy
Neurol 76:1782-1788, Seguin, J.et al, 2011
Paraneoplastic and Autoimmune Encephalitis
UpToDate, June, Dalmau, J.,et al, 2011
Treat Alzheimer Disease Before It Is Symptomatic
Arch Neurol 68:1237-1238, , 2011
Longitudinal Change of Biomakers in Cognitive Decline
Arch Neurol 68:1257-1266,1237, Lo, R.Y.,et al, 2011
Primary Central Nervous System Lymphoma
Arch Neurol 67:291-297, Gerstner,E.R. &Batchelor,T.T., 2010
High-Resolution Diffusion Tensor Imaging in the Substantia Nigra of De Novo Parkinson Disease
Neurol 72:1378-1384,1374, Vaillancourt,D.E.,et al, 2009
Outcome in Adult Low-Grade Glioma: The Impact of Prognostic Factors and Treatment
Neurol 69:1366-1373, Schiff,D.,et al, 2007
Disease-Modifying Therapies for Alzheimer Disease: Challenges to Early Intervention
Neurol 69:1622-1634, Cummings,J.L.,et al, 2007
Detection of CSF 14-3-3 Protein in Guillain-Barr Syndrome
Neurol 67:2211-2216, Bersano,A.,et al, 2006
Using Susceptibility-Based Imaging in Highly Active Late-Onset Multiple Sclerosis
Neurol 106:e214794, Sosa,S.M.,et al, 2026
Diagnostic Value of the Kappa Free light Chain Index to Distinguish MOGAD, NMOSD, and MS
Neurol 106:e214946, Tournier,A.,et al, 2026
Using Susceptibility-Based Imaging in highly ctive Late-Onset Multiple Sclerosis
Neurol 106:e214794, Sosa,S.M.,et al, 2026
Next-Day Serum Glial Fibrillary Acidic Protein Levels to Aid Diagnosis of Sport-Related Concussion
Neurol 104:e210308, OBrien,W.T.,et al, 2025
Predicting Individual Pain Sensitivity Using a Novel Cortical Biomarker Signature
JAMA Neurol 82:237-246, Chowdhury,N.S.,et al, 2025
Cancer-Related Cognitive Impairment in Patients with Lung Cancer
Neurol 104::e213651, Simo,M.,et al, 2025
Frequency and Diagnostic Implications of Paramagnetic Rim Lesions in People Presenting for Diagnosis to a Multiple Sclerosis Clinic
Neurol 105:e213912, Remner,B.,et al, 2025
Diagnosis of Multiple Sclerosis: 2024 Revisions of the McDonald Criteria
Lancet Neurol 24:850-865, Montalban,X.,et al, 2025
Inhibition of CD40L with Frexalimab in Multiple Sclerosis
NEJM 390:589-600, 662, Vermersch,P.,et al, 2024
Alzheimers Disease Biomarkers - Timing is Everything
NEJM 390:761-763, Mayeux,R., 2024
CSF and Plasma Biomarkers in Patients with Iatrogenic Cerebral Amyloid Angiopathy
Neurol 103:e209828, Pollaci,G.,et al, 2024
Revised Criteria for Diagnosis and Staging of Alzheimers Disease: Alzheimers Association Workgroup
Alzheimers Dement 20:5143-5169, Jack,Jr.,C.R.,et al, 2024
Kappa Free Light Chain Biomarkers are Efficient for the Diagnosis of Multiple Sclerosis
Neurol Neuroinflamm 10:e200049, Levraut,M.,et al, 2023